Immunotherapy is one of the most important advances of modern times within oncology. Unfortunately, many immunotherapies- particularly cytokine immunotherapies are toxic when given systemically. Despite a track-record of success in animal models, including dramatic tumor regressions, many of these cytokines have not been moved into broad human clinical trials because of serious, dose-limiting toxicities.
While progress has been made with immune checkpoint inhibitors, which release the "brakes" of the immune system, similar progress to stimulate the immune system directly has been lacking. NanoRED's platform can be used to package immunostimulatory cytokines and can deliver them directly into the tumor and tumor microenvironment. The combination of a tumor toxic compound in the liposomal shell and a potent immunostimulator creates an ideal training ground to educate the patient's immune system to eliminate cancer cells.
Our immunology platform is typified by our lead candidate- NR001 which packages an immunostimulatory cytokine in our patented liposomes. NanoRED has developed preclinical proof-of-concept demonstrating that our platform works in animal models.
We are also developing liposomes capable of delivering activation signals within the tumor that turn on chimeric antigen receptor T cells (CAR T), making CAR T safer and expanding the use of CAR T into solid tumors.
One of the major advantages of our platform is the ability to package many different agents, ranging from small molecules to proteins for clinician-triggered, tumor-specific release. This has enabled us to collaborate with other entities to customize our delivery platform to meet the unique needs of their therapeutics.
The broad spectrum of potential molecules that NanoRED's platform can deliver, along with our commitment to partnership are key elements of our strategy to roll our platform out for use in the treatment of many different cancers.
NanoRED's mission is to change the way that cancer is treated. To do this, we will pursue a rapid clinical trial strategy. Our initial target indications include soft tissue sarcomas, where our focus will initially be on orphan indications such as rhabdomyosarcoma, allowing for faster and more efficient clinical trials. Soft tissue sarcomas are highly vascular, and situated ideally for treatment with IR-activated therapies. In addition, the dramatic clinical need, coupled with Orphan Disease status enhances our ability to partner with other pharmaceutical entities to facilitate rapid development of NR001. Preclinical work has also validated our platform in mouse models of breast cancer.